PURPOSE: A sentinel lymph node biopsy (SLNB) has become the standard care for the staging of axilla in breast cancer and the increase in body weight with age has an inverse relationship to its success. Therefore, the characteristics of patients who underwent a SLNB, and the relationship of the influences of Body Mass Index (BMI) and age, were evaluated using lymphoscintigram visualization in a sentinel lymph node biopsy (SLNB) for breast cancer. METHODS: Between Sept. 1995 and Dec 2003, 238 patients underwent lymphoscintigraphy and SLNB (including full axillary node dissection with SLNB). 205 (86.1%) cases were able to be visualized by lymphoscintigraphy, But the remaining 33 (13.9%) were not. A combined technique (radioisotope and blue dye) was used to detect the SLNs. The BMI for each patient was calculated from height and weight data (kg/m2). RESULTS: A SLNB was attempted in all cases, but 5 failed. Of the 238 cases, the lymphoscintigraphy visualization was successful in 205 (86.1%) and failed in 33 (13.9%). The mean weight and BMI were significantly higher in the failure group. The success of a SLNB was inversely related to the BMI. When the subjects were divided into two group ac-coding to age (<50 year-old versus > or =50 year-old), this relationship was more pronounced in the > or =50 year-old group. CONCLUSION: The age and BMI of the patient influences the detection of the sentinel lymph node on a lymphoscintigram. There was no influence on the sentinel lymph node biopsy with increasing BMI and age. Therefore, increased age and/or BMI alone do not appear to be contraindication for a sentinel lymph node biopsy in older or overweight patients.
Axilla ; Body Mass Index* ; Body Weight ; Breast Neoplasms* ; Breast* ; Humans ; Lymph Nodes* ; Lymphoscintigraphy* ; Overweight ; Sentinel Lymph Node Biopsy

PURPOSE: For the accurate diagnosis of non-palpable breast lesions with microcalcification, a localization and biopsy procedure should be performed by using mammography. Recently, a stereotactic vacuum-assisted biopsy has been reported as a convenient and accurate method for a procedure. This study was performed to determine whether the upright add-on type stereotactic biopsy was suitable for the diagnosis of microcalcified breast lesions in Korean women. METHODS: Between April 2002 and March 2003, an upright add-on type stereotactic vacuum-assisted biopsy was performed in 21 cases with microcalcification; that had been categorized from 2 to 5 according to the BI-RADS (Breast Imaging Reporting and Data System). The microcalcified lesions in biopsy specimens were confirmed with tissue mammogram and a pathological review performed. RESULTS: The pathological findings revealed fibrocystic changes in 15 cases, intraductal papilloma in 1 and ductal carcinoma in situ (DCIS) in 5. There were no malignancy among the BI-RADS category 2 & 3 cases, but DCIS was found in 2 (25%) out of 8 BI-RADS category 4 cases, and in all 3 (100%) of BI-RADS category 5 cases. The malignancy detection rate among the cases with microcalcification with a BI-RADS category above 4 was 45.4% (5/11). CONCLUSION: An upright add-on type stereotactic vacuum assisted biopsy is an accurate, safe and very convenient tool for the diagnosis of breast lesions with microcalcification.
Biopsy* ; Breast* ; Carcinoma, Intraductal, Noninfiltrating ; Diagnosis* ; Female ; Humans ; Mammography ; Papilloma, Intraductal ; Vacuum

PURPOSE: The main clinical significance of HER-2/neu gene amplification is derived from its use as (a) a prognostic indicator, (b) a predictive factor for the sensitivity to chemotherapy, and (c) the identification of cases that are eligible for a specific therapy targeting the HER-2/neu protein. Over- expression of HER-2/neu has been shown to be associated with a poor prognosis for patients with node-positive breast cancer and also possibly for patients with node-negative breast cancer. The purpose of this work was to analyze the HER-2/neu gene amplification and correlate it with other clinico-pathologic parameters. METHODS: The study population consisted of 194 patients with breast cancer who had been treated with curative surgery at the Kangdong Sacred Hospital, Seoul, Korea from 1995 to 2000. Paraffin-embedded tissue samples from the primary tumors were obtained from the hospital archives and the tissue microarray was then constructed. We analyzed the amplification of HER-2/neu gene by the two-color FISH (Fluorescence in situ hybridization) method, and we correlated the results with other clinico-pathologic parameters such as tumor size, stage, histologic grade, lymph node status and hormonal receptor status. RESULTS: For 44 cases (22.7%) of a total 194 cases, the HER-2/neu gene was amplified. HER-2/neu gene amplification was positively correlated with TNM stage and lymph node status, and it was inversely correlated with estrogen receptor positivity. CONCLUSION: For breast cancer, the analysis of the HER-2/neu gene by FISH based on a tissue microarray may be useful.
Breast Neoplasms* ; Breast* ; Drug Therapy ; Estrogens ; Gene Amplification ; Humans ; Korea ; Lymph Nodes ; Prognosis ; Seoul

PURPOSE: Breast cancer is a common malignant tumor for Korean women. Various oncogenes have been demonstrated in malignant tumor cells. There were many reports on the relationship between the prognosis and the tumor markers, and particularly for HER-2/neu; however, this relationship is controversial. The aim of this study was to perform immunohistochemical staining for the HER-2/neu antigenic protein in breast cancer patients to evaluate the expression rate of this antigenic protein, and to compare the correlations with the patients' prognosis. METHODS: The medical records of 100 patients who were diagnosed with breast cancer and who were treated with mastectomy between January 1996 and December 1999 at Soonchunhyang University Cheonan Hospital were selected according to the tissue condition of the paraffin block fixations. The prognostic factors were then investigated. The immunohistochemical expression of HER-2/neu was examined and compared with the survival rate using a Kaplan-Meier estimate and a log rank test. RESULTS: One hundred patients were included in this study, had a mean (SD) age of 47.9 (plus or minus 10.5) years and a follow-up duration of 59.9 (plus or minus 13.3) moths The overall mortality was 35% (35/100) and the mean survival time (SD) was 64.4 (plus or minus 12.0) months. The overall 5-year survival rate was 77.0%. Among the study variables, the tumor stage was a significant predictor of survival, and it as associate with a significantly low survival rate for stage III tumor. Lymph node metastasis, hormonal receptor status, histologic grade and HER-2/neu overexpression were significantly associated with the survival rate for patients with breast cancer. CONCLUSION: HER-2/neu is a very useful prognostic factor, and statistical significance was achieved for this factor.
Breast Neoplasms* ; Breast* ; Chungcheongnam-do ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymph Nodes ; Mastectomy ; Medical Records ; Mortality ; Moths ; Neoplasm Metastasis ; Oncogenes ; Paraffin ; Prognosis ; Survival Rate ; Biomarkers, Tumor

PURPOSE: Survivin is a member of the inhibitor of apoptosis (IAP) family, which is also involved in the regulation of cell division and is also overexpressed and associated with parameters of poor prognosis in most human cancers, including carcinomas of the lung, breast, colon, stomach, esophagus and pancreas. This study examined the expression patterns of survivin in normal breast tissue, atypical hyperplasia, primary breast cancer and lymph node tissues involved with breast cancer and to determined whether the expression of survivin is associated with the characteristics and prognosis of breast cancer. METHODS: Formalin-fixed paraffin-embedded samples from 80 breast cancer, 20 atypical hyperplasia and 20 malignant lymph node tissue cases were immunostained using polyclonal survivin (Novus Biologicals, CO). The degree of immunostaining was recorded on a scale of 0-3 according to the percentages of staining and distributions within the cytoplasm & nucleus. RESULTS: Survivin was expressed in 52, 14 and 17 of the 80 breast cancer (65%), atypical hyperplasia (70%) and breast cancer lymphoid (85%) specimens respectively. Among those expressing cancer, 11.3, 31.3 and 22.5% demonstrated nuclear staining only, cytoplasmic staining only and both nuclear and cytoplasmic staining respectively. A statistical analysis revealed that cytoplasmic survivin expression was correlated with the stage, histological grade and L/N metastasis. In a Cox proportional hazard model analysis, the expression of survivin was not identified as a significant independent predictor of overall survival (P=0.168), although the decrease in the survival rate of survivin-positive patients did reach statistical significance (P=0.048). CONCLUSION: Our results show that survivin is frequently overexpressed in primary breast cancer and its expression gradually increased from normal breast tissue to malignant lymph nodes. The expression of cytoplasmic survivin was common in breast cancer and could be both a useful diagnostic marker and important source of prognostic information.
Apoptosis ; Breast Neoplasms* ; Breast* ; Cell Division ; Colon ; Cytoplasm ; Esophagus ; Humans ; Hyperplasia ; Lung ; Lymph Nodes ; Neoplasm Metastasis ; Pancreas ; Prognosis ; Proportional Hazards Models ; Stomach ; Survival Rate

PURPOSE: Drug resistance plays an important role in the failure of chemotherapy in breast cancer. The purpose of the study was to investigate the chemosensitive and chemoresistance indices of breast carcinomas and see if the in vitro chemosensitivity test correlated with the prognostic indices. METHODS: The immunohistochemical expressions of MDR1, MRP1 and topoisomerase IIalpha(topo IIalpha) were studied and then correlated these with the in vitro chemosensitivities using the histoculture drug response assay (HDRA) and clinicopathological factors in 51 breast carcinomas. RESULTS: In the breast carcinomas examined, the immunohistochemical expressions of MDR1, MRP1 and topo II alpha were strongly observed in 26 (51.0%), 16 (32.0%), 15 (31.3%) carcinomas, respectively. The MRP1 was more frequently expressed in poorly differentiated carcinomas (P= 0.006), and those of MDR1 and topo II alpha were more frequently observed in tumor overexpressing cerbB2 (P=0.038, P=0.036). The expression of MDR1 was related to that of topo II alpha (P=0.015). Comparing these markers with the in vitro chemosensitivities to cyclophosphamide, 5-FU, adriamycin, taxol and taxotere, no correlations were found between the expression of MDR1, MRP1, and topo II alpha but from the chemosensitivity using the HDRA, the growth inhibition rate for cyclophosphamide was higher in MRP1 expressing carcinomas (P=0.009). CONCLUSION: MDR1, MRP1 and topo II alpha were all found to be associated with the poor prognostic indices, but assessment of their immunohistochemical expressions did not allow for prediction of the response to chemotherapy by the in vitro chemosensitivity test in breast carcinomas.
Breast Neoplasms* ; Breast* ; Cyclophosphamide ; Doxorubicin ; Drug Resistance ; Drug Therapy ; Fluorouracil ; Paclitaxel

PURPOSE: The extent of the loss of heterozygosity (LOH) has been used as the genetic parameter for the classification and staging of some solid tumors. Breast cancers such as ductal carcinoma in situ (DCIS), and invasive and metastatic lesions, are frequently observed to contain heterogeneous tumor foci. To delineate the relation between the LOH and the progression of breast cancers, three successive histological sites in a tumor lesion were analyzed for LOH events. METHODS: We tested 111 tumor site including DCIS, and invasive, and metastatic lymph nodes from 50 breast cancers for LOH using 5 microsatellite makers on 8 chromosomal arms (3p, 4p, 5q, 8p, 9p, 13q, 17p, & 18q). RESULTS: Twenty-four of 34 breast cancers showing intratumoral histological heterogeneity had common chromosomal losses in the heterogeneous tumor sites, as well as having divergent losses that were restricted to a part of tumor lesion (mean divergent loss, 2.32). The number and frequency of heterogeneous chromosomal losses were not significantly related with age, tumor size, and stage. Overall, at least one chromosomal loss was detected in 48 cases, and incidences of LOH in each chromosome were 27.1~63.3%. A large fraction (58%) of breast cancer patients had 2 to 4 chromosomal losses, and chromosome 8p was most frequently lost (63%). When comparing the number of chromosomal losses in nine cases with all of three progressive lesions, the lost extent was greater in the DCIS (mean losses, 4.44) than in the invasive sites (mean losses, 3.1) and the metastatic lymph nodes (mean losses, 2.9). Moderate-level chromosomal losses involving 3-5 chromosomes were significantly related with lymph node metastasis (p=0.006) and the advanced tumor stage (p<0.005), whereas low-level losses involving 1~2 chromosomes and high-level losses involving 6~7 chromosomes were more common in DCIS and early-stage diseases. CONCLUSION: The DCIS, invasive, and metastatic sites of a breast cancer patient contained common and divergent chromosomal losses. This indicates the concurrent expansion of different subclones was derived from a common ancestor clone, in which an optimal range of chromosomal losses, rather than high-level chromosomal losses, was more frequently associated with lymph node metastasis and the advanced tumor stages.
Arm ; Breast Neoplasms* ; Breast* ; Carcinoma, Intraductal, Noninfiltrating ; Classification* ; Clone Cells ; Humans ; Incidence ; Loss of Heterozygosity ; Lymph Nodes ; Microsatellite Repeats ; Neoplasm Metastasis ; Population Characteristics

Breast metastases from extramammary primary tumors are uncommon, accounting for approximately 1.3~6.6% of all malignant mammary tumors. Apart from hematopoietic neoplasms, malignant melanoma is one of the most common neoplasms with which secondary involvement of the mammary parenchyme is known. Although they are so rare, breast metastases from such neoplasms can mimic primary breast carcinoma clinically and on imaging studies. Approximately 20% of the patients affected by malignant melanoma will develop metastases, the commonest sites being liver, lung, and brain; metastases to the breast from malignant melanoma are rare, and in about 40% of the patients affected the breast lesion is the first manifestation of disease. Correct management of metastatic disease to the breast can prevent unnecessary mutilation; in fact, in the majority of patients so far widespread metastases have appeared rapidly despite various systemic treatments, showing that major surgery gives very poor results in terms of controlling the disease. In this paper, we present the case of a 49-year-old woman with a history of a malignant cutaneous melanoma of nasal cavity that had been surgically excised in 2004. She was admitted to our Breast Division 6 months later because a screening mammogram and anultrasound evaluation had revealed the presence of a nodular opacity in the both breast, without any clinical manifestations. For this reason, in September 2004 the patient underwent a simple mastectomy of both breasts.
Brain ; Breast Neoplasms ; Breast* ; Female ; Hematologic Neoplasms ; Humans ; Liver ; Lung ; Mass Screening ; Mastectomy, Simple ; Melanoma* ; Middle Aged ; Nasal Cavity ; Neoplasm Metastasis*

PURPOSE: Hyperthermia treatments (Laser, Macrowave, Microwave, Electromagnetic force, and Ultrasonic heating system etc.) haves been used for the purpose tof destroying the focus part of tumors. Interstitial Laser Photocoagulation (ILP), originally attempted by Bown in 1983, experimentally makes use of Nd:YAG Laser in breast cancer. This study attempted to evaluate the effect of ILP for the fibroadenomas of the breast under the local anesthesia. METHODS: From the physical examination findings, breast ultrasonogram, mammogram and Fine Needle Aspiration Cytology of 74 unmarried women patients, diagnosed as having a fibroadenoma, which is a breast benign tumor, who took ILP treatment and could be followed up based on their medical records 62 were examined and analyzed. After checking the accurate positioning of the optical fiber in the tumor, through an ultrasonogram under the local anesthesia, the ILP treatment was conducted using a Diode Laser (Diomed(r) Ltd.). RESULTS: The average age of the patients was 23 years, and the mean sizes of the tumors were as 1.6 and 1.8 cm on physical examination and 1.8 cm on the ultrasonogram, respectively. There were significant decreases in the clinical and sonographic sizes following the treatment (P<0.05, P<0.01). From a comparison of the tumor sizes before and after the ILP treatment, the tumor reduction rates from the physical examination and ultrasonogram findings were 92 and 80%, respectively, when the size of the tumors was below 1 cm, and the disappearance rates were 92% and 80%, respectively, when the size of the tumors was below 1 cm. CONCLUSION: Interstitial laser photocoagulation is a safe, precise, minimally invasive, and cosmetic procedure for the in situ destruction of breast fibroadenomas.
Anesthesia, Local ; Biopsy, Fine-Needle ; Breast Neoplasms ; Breast* ; Female ; Fever ; Fibroadenoma* ; Heating ; Hot Temperature ; Humans ; Lasers, Semiconductor ; Light Coagulation* ; Magnets ; Medical Records ; Microwaves ; Optical Fibers ; Physical Examination ; Single Person ; Ultrasonics ; Ultrasonography

Purpose: Breast cancer is one of the most frequent malignant tumors in American and European countries, with incidences increasing every year. In Korea it was the second most frequent cancer in 2002, followed by stomach cancer. However, in 2001 the incidence of breast cancer was first, followed by colon cancer, with incidences increasing every year. Conversely, breast cancer in men is not frequent, with an incidence of less than 1%, according to studies from both Korea and abroad. Studies on the treatment methods and prognostic factors of breast cancer in men are limited, with little clinical experience. Although there was difficulty in collecting complete data, due to lack of awareness of male breast cancer, the clinical characteristics could be determined from the experience and treatment outcomes of male breast cancer patients. Methods: The medical records of 13 male patients with breast cancer, who could be followed up, were retrospectively evaluated from 4809 patients with breast cancer, evaluated between 1989 and 2003. Results: The average age of the subjects was 64.3 years, with the breast masses with no pain situated at the center of the breast in most cases. The affected period in most patients was 1 year, with most having stage II breast cancer. Conclusion: Although asymptomatic unilateral subareolar breast mass in old ages is the most frequent symptom, most missed the period for early treatment due to lack of awareness of male breast cancer, therefore, their breast cancer had been for more than a year. Despite the difficulty due to the lack of data, attention needs to paid, and continuous studies required, toward male breast cancer.
Breast Neoplasms ; Breast Neoplasms, Male ; Breast* ; Colonic Neoplasms ; Humans ; Incidence ; Korea ; Male* ; Medical Records ; Multiple Endocrine Neoplasia Type 1 ; Retrospective Studies ; Stomach Neoplasms